GA NCORP

TRIALS & PROVIDERS

Menu

NCORP Trials

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT06297226
Protocol IDs
CA088-1000 (primary)
NCI-2024-02712
Study Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCI Full Details
http://clinicaltrials.gov/show/NCT06297226

Summary

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in
participants with relapsed or refractory multiple myeloma.

Treatment Sites


 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
CALL EMAIL

Copyright © 2015, Georgia NCI Community Oncology Research Program. All Rights Reserved.
Powered by GeorgiaCancerInfo.org
Website Design & Development by Peachtree Solutions.